IceCure Medical Reports 70% Increase in U.S. ProSense Install Base
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense for breast cancer cryoablation following FDA marketing authorization in October 2025, reflecting accelerating commercial adoption, expanding physician demand and continued growth in the Company's U.S. footprint. IceCure develops and commercializes its minimally invasive cryoablation technology that destroys tumors by freezing, offering an option to surgical tumor removal for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.930
Low
3.00
Averages
3.00
High
3.00
Current: 5.930
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IceCure Medical Highlights Cryoablation Study in Top Surgical Journal
- Significant Clinical Outcomes: A study published by IceCure Medical in the International Journal of Surgery demonstrates that the ProSense® cryoablation technology shows clinical advantages over radiofrequency ablation (RFA) in treating early-stage breast cancer, particularly in tumor control rates and patient recovery, indicating its potential for widespread application.
- Strategic Focus on Japan: IceCure is preparing to present its findings at the 2026 Japanese Breast Cancer Society meeting and is collaborating with Terumo, one of Japan's largest medical device companies, to submit ProSense® for regulatory approval to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026, further expanding its market reach.
- Distinct Technical Advantages: The research indicates that cryoablation provides local tumor control rates comparable to breast-conserving surgery for patients with small breast tumors, while offering shorter procedure times and improved cosmetic outcomes, thereby enhancing treatment options for patients.
- Enhanced Industry Recognition: The publication in the International Journal of Surgery, ranked third globally among surgical journals, not only boosts the recognition of ProSense® within the industry but may also accelerate global physician interest in cryoablation technology, promoting its adoption in breast cancer treatment.
See More
IceCure Medical Completes Private Placement Financing
- Financing Size: IceCure Medical has entered into securities purchase agreements with a single healthcare-focused institutional investor for the sale of 1,833,334 ordinary shares and corresponding Series D and E Warrants, with expected gross proceeds of approximately $5.5 million, reflecting investor confidence in its cryoablation technology.
- Warrant Terms: Both Series D and E Warrants have an exercise price of $3.00 per share and can be exercised immediately, which is expected to provide additional liquidity to the company to support its operations and R&D activities.
- Shareholder Approval: The company plans to reduce the exercise price of the March 2026 Series B and C Warrants from $16.50 to $3.00 upon obtaining shareholder approval, a move aimed at boosting investor confidence and facilitating future financing.
- Market Positioning: IceCure focuses on developing liquid nitrogen-based cryoablation systems primarily targeting breast, kidney, bone, and lung tumors, and with its minimally invasive technology, it is expected to enhance its competitive edge and expand its market share in the global healthcare sector.
See More
IceCure Medical Completes Private Placement Financing
- Financing Scale: IceCure Medical has entered into agreements with a single healthcare-focused institutional investor to sell 1,833,334 ordinary shares along with Series D and E Warrants, expecting gross proceeds of approximately $5.5 million, which reflects the company's appeal in the capital markets and investor confidence.
- Warrant Details: Both Series D and E Warrants have an exercise price of $3.00 per share and can be exercised immediately, which is expected to enhance the company's liquidity and strengthen its competitive position in the tumor treatment sector.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and other general corporate purposes, indicating IceCure's commitment to advancing its innovative treatment technologies while maintaining financial stability and sustainable growth.
- Shareholder Approval: The company plans to amend the exercise price of the Series B and C Warrants issued in March 2026 from $16.50 to $3.00, contingent upon shareholder approval, thereby reducing financial pressure on investors and maximizing shareholder value.
See More
IceCure Medical Receives FDA Authorization, Shares Surge 200%
- FDA Authorization Impact: IceCure Medical's ProSense system received FDA marketing authorization in October 2025, leading to a 70% increase in its active U.S. commercial install base for breast cancer treatment, indicating a significant rise in market acceptance and potential revenue growth.
- Stock Surge: Following the positive news, IceCure Medical's shares skyrocketed over 200% on Wednesday, and if gains hold, it will mark the best day since August 2021, reflecting strong market confidence and investor optimism in the company's prospects.
- Optimistic Market Outlook: CEO Eyal Shamir noted that with growing physician interest and increased patient awareness, the company believes it remains in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S., with plans to expand its installed base and support.
- Positive Analyst Ratings: According to Koyfin, all three analysts covering ICCM rate it 'Buy' or higher, with an average price target of $44.50, representing nearly 2000% potential upside from the stock's last closing price, showcasing strong market confidence in its future performance.
See More
NeOnc Technologies Secures International Drug Authorization for NEO212
- International Drug Authorization: NeOnc Technologies has secured Investigational New Drug authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant milestone in neuro-oncology and expected to accelerate its global market expansion.
- Clinical Trial Progress: The Phase 2a study for NEO100 has achieved full enrollment, with preliminary data indicating approximately 24% tumor remission in recurrent glioblastoma patients, showcasing the potential market value of this therapy.
- Insider Investment Confidence: CEO Amir Heshmatpour has personally invested over $500,000 recently, reflecting strong management confidence in the company's future, with total insider purchases nearing $1 million over the past year.
- Financial Support: NeOnc Technologies has access to a $75 million at-the-market facility and a $10 million line of credit, providing robust financial backing for advancing multiple clinical programs.
See More
IceCure Medical Sees Significant Growth Post FDA Approval
- Market Expansion: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, indicating accelerated commercial adoption and rising physician demand in the U.S. market.
- Clinical Acceptance Growth: The American Society of Breast Surgeons (ASBrS) recently updated its resource guidelines to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical acceptance of minimally invasive breast cancer therapies.
- Increased Patient Awareness: Patient awareness of breast cancer cryoablation continues to grow as ProSense® receives extensive media coverage, with approximately 190 CBS and CW-affiliated stations highlighting cryoablation as a minimally invasive alternative to surgery, further driving demand.
- Lead Generation Surge: At two major breast health conferences this year, IceCure generated significantly more sales leads for ProSense® systems compared to previous events, reflecting a substantial increase in interest from physicians and healthcare providers, indicating potential for future commercial opportunities.
See More
IceCure Medical Highlights Cryoablation Study in Top Surgical Journal
- Significant Clinical Outcomes: A study published by IceCure Medical in the International Journal of Surgery demonstrates that the ProSense® cryoablation technology shows clinical advantages over radiofrequency ablation (RFA) in treating early-stage breast cancer, particularly in tumor control rates and patient recovery, indicating its potential for widespread application.
- Strategic Focus on Japan: IceCure is preparing to present its findings at the 2026 Japanese Breast Cancer Society meeting and is collaborating with Terumo, one of Japan's largest medical device companies, to submit ProSense® for regulatory approval to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026, further expanding its market reach.
- Distinct Technical Advantages: The research indicates that cryoablation provides local tumor control rates comparable to breast-conserving surgery for patients with small breast tumors, while offering shorter procedure times and improved cosmetic outcomes, thereby enhancing treatment options for patients.
- Enhanced Industry Recognition: The publication in the International Journal of Surgery, ranked third globally among surgical journals, not only boosts the recognition of ProSense® within the industry but may also accelerate global physician interest in cryoablation technology, promoting its adoption in breast cancer treatment.
See More
IceCure Medical Completes Private Placement Financing
- Financing Size: IceCure Medical has entered into securities purchase agreements with a single healthcare-focused institutional investor for the sale of 1,833,334 ordinary shares and corresponding Series D and E Warrants, with expected gross proceeds of approximately $5.5 million, reflecting investor confidence in its cryoablation technology.
- Warrant Terms: Both Series D and E Warrants have an exercise price of $3.00 per share and can be exercised immediately, which is expected to provide additional liquidity to the company to support its operations and R&D activities.
- Shareholder Approval: The company plans to reduce the exercise price of the March 2026 Series B and C Warrants from $16.50 to $3.00 upon obtaining shareholder approval, a move aimed at boosting investor confidence and facilitating future financing.
- Market Positioning: IceCure focuses on developing liquid nitrogen-based cryoablation systems primarily targeting breast, kidney, bone, and lung tumors, and with its minimally invasive technology, it is expected to enhance its competitive edge and expand its market share in the global healthcare sector.
See More
IceCure Medical Completes Private Placement Financing
- Financing Scale: IceCure Medical has entered into agreements with a single healthcare-focused institutional investor to sell 1,833,334 ordinary shares along with Series D and E Warrants, expecting gross proceeds of approximately $5.5 million, which reflects the company's appeal in the capital markets and investor confidence.
- Warrant Details: Both Series D and E Warrants have an exercise price of $3.00 per share and can be exercised immediately, which is expected to enhance the company's liquidity and strengthen its competitive position in the tumor treatment sector.
- Use of Proceeds: The net proceeds from this offering will be allocated for working capital and other general corporate purposes, indicating IceCure's commitment to advancing its innovative treatment technologies while maintaining financial stability and sustainable growth.
- Shareholder Approval: The company plans to amend the exercise price of the Series B and C Warrants issued in March 2026 from $16.50 to $3.00, contingent upon shareholder approval, thereby reducing financial pressure on investors and maximizing shareholder value.
See More
IceCure Medical Receives FDA Authorization, Shares Surge 200%
- FDA Authorization Impact: IceCure Medical's ProSense system received FDA marketing authorization in October 2025, leading to a 70% increase in its active U.S. commercial install base for breast cancer treatment, indicating a significant rise in market acceptance and potential revenue growth.
- Stock Surge: Following the positive news, IceCure Medical's shares skyrocketed over 200% on Wednesday, and if gains hold, it will mark the best day since August 2021, reflecting strong market confidence and investor optimism in the company's prospects.
- Optimistic Market Outlook: CEO Eyal Shamir noted that with growing physician interest and increased patient awareness, the company believes it remains in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S., with plans to expand its installed base and support.
- Positive Analyst Ratings: According to Koyfin, all three analysts covering ICCM rate it 'Buy' or higher, with an average price target of $44.50, representing nearly 2000% potential upside from the stock's last closing price, showcasing strong market confidence in its future performance.
See More
NeOnc Technologies Secures International Drug Authorization for NEO212
- International Drug Authorization: NeOnc Technologies has secured Investigational New Drug authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant milestone in neuro-oncology and expected to accelerate its global market expansion.
- Clinical Trial Progress: The Phase 2a study for NEO100 has achieved full enrollment, with preliminary data indicating approximately 24% tumor remission in recurrent glioblastoma patients, showcasing the potential market value of this therapy.
- Insider Investment Confidence: CEO Amir Heshmatpour has personally invested over $500,000 recently, reflecting strong management confidence in the company's future, with total insider purchases nearing $1 million over the past year.
- Financial Support: NeOnc Technologies has access to a $75 million at-the-market facility and a $10 million line of credit, providing robust financial backing for advancing multiple clinical programs.
See More
IceCure Medical Sees Significant Growth Post FDA Approval
- Market Expansion: Following FDA marketing authorization in October 2025, IceCure Medical reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation, indicating accelerated commercial adoption and rising physician demand in the U.S. market.
- Clinical Acceptance Growth: The American Society of Breast Surgeons (ASBrS) recently updated its resource guidelines to recommend cryoablation as a local treatment option for low-risk breast cancer patients, marking a significant milestone in the clinical acceptance of minimally invasive breast cancer therapies.
- Increased Patient Awareness: Patient awareness of breast cancer cryoablation continues to grow as ProSense® receives extensive media coverage, with approximately 190 CBS and CW-affiliated stations highlighting cryoablation as a minimally invasive alternative to surgery, further driving demand.
- Lead Generation Surge: At two major breast health conferences this year, IceCure generated significantly more sales leads for ProSense® systems compared to previous events, reflecting a substantial increase in interest from physicians and healthcare providers, indicating potential for future commercial opportunities.
See More
